A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study

BackgroundIn this work, we aim to develop and validate a fast, simple, and sensitive method for the quantitative determination of flibanserin and the exploration of its pharmacokinetics.MethodsUltra-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was the method of choice for this investigation and carbamazepine was selected as an internal standard (IS). The plasma samples were processed by one-step protein precipitation using acetonitrile. The highly selective chromatographic separation of flibanserin and carbamazepine (IS) was realised using an Agilent RRHD Eclipse Plus C18 (2.1 × 50 mm, 1.8 µ) column with a gradient mobile phase consisting of 0.1% formic acid in water and acetonitrile. The analytes were detected using positive-ion electrospray ionization mass spectrometry via multiple reaction monitoring (MRM). The target fragment ions were m/z 391.3 → 161.3 for flibanserin and m/z 237.1 → 194 for carbamazepine (IS). The method was validated by linear calibration plots over the range of 100–120,000 ng/mL for flibanserin (R2 = 0.999) in rat plasma.ResultsThe extraction recovery of flibanserin was in the range of 91.5–95.8%. The determined inter- and intra-day precision was below 12.0%, and the accuracy was from − 6.6 to 12.0%. No obvious matrix effect and astaticism was observed for flibanserin. The target analytes were long-lasting and stable in rat plasma for 12 h at room temperature, 48 h at 4 °C, 30 days at − 20 °C, as well as after three freeze–thaw cycles (from − 20 °C to room temperature). The proposed method has been fully validated and successfully applied to the pharmacokinetic study of flibanserin.

• Publication year

  2019

• Venue

  BMC Chemistry

• Publication date

  2019-08-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1186/s13065-019-0620-9PMID 31463480PMCID 6710871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An UPLC–MS/MS method for the quantitation of alectinib in rat plasma

  2017cited by this paper
• Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.

  2016cited by this paper
• A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study.

  2016cited by this paper
• Euthanasia using gaseous agents in laboratory rodents

  2016cited by this paper
• Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry.

  2015cited by this paper
• Determination of N-methylcytisine in rat plasma by UPLC-MS/MS and its application to pharmacokinetic study.

  2015cited by this paper
• Enantioselective HPLC determination and pharmacokinetic study of secnidazole enantiomers in rats.

  2014cited by this paper
• Analytical quality-by-design approach for sample treatment of BSA-containing solutions

  2014cited by this paper
• Determination of flibanserin and tadalafil in supplements for women sexual desire enhancement using high-performance liquid chromatography with tandem mass spectrometer, diode array detector and charged aerosol detector.

  2014cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.

  2013cited by this paper
• Open-label extension study of flibanserin in women with hypoactive sexual desire disorder.

  2012cited by this paper
• Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.

  2012cited by this paper
• Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.

  2011cited by this paper
• Circuits of sexual desire in hypoactive sexual desire disorder.

  2010cited by this paper
• The Dual Control Model: Current Status and Future Directions

  2009cited by this paper
• Pathways of sexual desire.

  2009cited by this paper
• Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women.

  2008cited by this paper
• Pharmacology of flibanserin.

  2006cited by this paper
• ACCOMMODATING THE FETAL ALCOHOL SPECTRUM DISORDERS IN THE DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS (DSM V)

  2006cited by this paper
• Distress About Sex: A National Survey of Women in Heterosexual Relationships

  2003cited by this paper
• The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function

  2000cited by this paper
• Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant.

  1997cited by this paper

• Determination of Flibanserin in Female Sexual Desire Enhancer Products by LC-MS/MS and Its Confirmation by LCMS-IT-TOF.

  2026cites this paper
• Development of Spraying Based Liquid Phase Microextraction Method for the Preconcentration of Flibanserin From Urine Samples via GC-MS Analyses.

  2025cites this paper
• Zirconium-based hydrophobic-MOFs as innovative electrode modifiers for flibanserin determination: Exploring the electrooxidation mechanism using a comprehensive spectroelectrochemical study

  2024cites this paper
• A Different Perspective on the Characterization of a New Degradation Product of Flibanserin With HPLC–DAD–ESI-IT-TOF-MSn and Its Pharmaceutical Formulation Analysis With Inter-Laboratory Comparison

  2023cites this paper
• Development and validation of a novel evaporation setup-assisted TLC method with fluorescence detection for determination of flibanserin in pharmaceutical and biological samples.

  2022cites this paper
• Emphasis on the incorporation of Tropaeolin OO dye and silver nanoparticles for voltammetric estimation of flibanserin in bulk form, tablets and human plasma.

  2022cites this paper
• A systematic UHPLC-Q-TOF-MS/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway.

  2021cites this paper
• Second-derivative synchronous fluorimetry and time-programmed HPLC-fluorescence detection for simultaneous estimation of flibanserin and sitagliptin phosphate in synthetic mixtures and human plasma samples.

  2021cites this paper
• Insights into flibanserin oxidative stress degradation pathway: in silico – in vitro toxicity assessment of its degradates

  2021cites this paper
• A novel design and facile synthesis of nature inspired poly (dopamine-Cr3+) nanocubes decorated reduced graphene oxide for electrochemical sensing of flibanserin

  2021cites this paper
• A rapid and sensitive stability-indicating green RP-HPTLC method for the quantitation of flibanserin compared to green NP-HPTLC method: Validation studies and greenness assessment

  2021cites this paper
• Quantitative Determination of Quercitrin Levels in Rat Plasma Using UHPLC-MS/MS and its Application in a Pharmacokinetic Study after the Oral Administration of Polygoni Cuspidati Folium Capsules.

  2021cites this paper
• Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

  2021cites this paper
• Mass spectrometry based rapid quantitative bioanalysis of flibanserin; pharmacokinetic and brain tissue distribution study.

  2020cites this paper
• Identification and determination of chemical constituents of Citrus reticulata semen through ultrahigh-performance liquid chromatography combined with Q Exactive Orbitrap tandem mass spectrometry.

  2019cites this paper